Casr-Inhibitor Treatment Prevents Hypertension Induced Cardiac Fibrosis and Remodeling
Affiliation
Department of Cardiology, the First Affiliated Hospital of Harbin Medical University, Harbin150001, and Heilongjiang Province, China
Corresponding Author
Department of Cardiology, the First Affiliated Hospital of Harbin Medical University, No.23, You Zheng Street, Nan Gang District, Harbin 150001, Heilongjiang Province, China, Tel: 86 451 85555063; E-mail: yinxinhua5063@163.com
Citation
Yin, X., et al. Casr-Inhibitor Treatment Prevents Hypertension Induced Cardiac Fibrosis and Remodeling. (2018) J Heart Cardiol 4(1): 6- 10.
Copy rights
© 2018 Yin, X. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License.
Keywords
Abstract
Introduction: Myocardial fibrosis induced by hypertension results in cardiac remodeling and dysfunction. It has been demonstrated that calcium sensing receptor (CaSR) activation is involved in calcium overload during cardiac fibrosis. This study investigated the role of Calhex231, a CaSR inhibitor in preventing cardiac fibrosis in a model of hypertension in spontaneously hypertensive rat (SHR).
Methods and results: Wistar Kyoto (WKY) rats were used in this study as normotensive controls. Cardiac function, hypertrophy index and blood pressure were determined at the end of the study. The results showed that Calhex231 treatment reduced the blood pressure, cardiac fibrosis and extracellular matrix (ECM) secretion in SHRs. Moreover, western blot results showed that the elevated expression levels of CaSR, matrix metalloproteinase-2 and -9 (MMP-2 and -9) induced by hypertension were suppressed by Calhex231 administration.
Conclusions: We found inhibition of CaSR through decreasing the deposition of ECM can treat cardiac remodeling.
